REGN
E579608
REGN is the stock ticker symbol for Regeneron Pharmaceuticals, a major U.S.-based biotechnology company known for developing innovative antibody-based therapies.
Statements (45)
| Predicate | Object |
|---|---|
| instanceOf | stock ticker symbol ⓘ |
| associatedWithIndustry | biotechnology ⓘ |
| associatedWithSector | healthcare ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| currency | USD NERFINISHED ⓘ |
| exchangeMarket | NASDAQ Global Select Market NERFINISHED ⓘ |
| hasCUSIP | 75886F107 ⓘ |
| hasISIN | US75886F1075 ⓘ |
| hasUnderlyingCompanyBusinessModel | research, development, manufacturing, and commercialization of biologic medicines ⓘ |
| hasUnderlyingCompanyCEO | Leonard S. Schleifer NERFINISHED ⓘ |
| hasUnderlyingCompanyCoFounder |
George D. Yancopoulos
NERFINISHED
ⓘ
Leonard S. Schleifer NERFINISHED ⓘ |
| hasUnderlyingCompanyCollaboration | Sanofi NERFINISHED ⓘ |
| hasUnderlyingCompanyCOVID19Involvement | developed REGEN-COV for COVID-19 treatment ⓘ |
| hasUnderlyingCompanyEmployeeType | research-intensive workforce ⓘ |
| hasUnderlyingCompanyExchangeListing | NASDAQ:REGN NERFINISHED ⓘ |
| hasUnderlyingCompanyFocus | biopharmaceutical research and development ⓘ |
| hasUnderlyingCompanyFoundedYear | 1988 ⓘ |
| hasUnderlyingCompanyHeadquarters | Tarrytown, New York, United States NERFINISHED ⓘ |
| hasUnderlyingCompanyIncorporationCountry | United States NERFINISHED ⓘ |
| hasUnderlyingCompanyLegalName | Regeneron Pharmaceuticals, Inc. NERFINISHED ⓘ |
| hasUnderlyingCompanyNotableProduct |
Dupixent (dupilumab)
NERFINISHED
ⓘ
Eylea (aflibercept) NERFINISHED ⓘ REGEN-COV (casirivimab and imdevimab) NERFINISHED ⓘ |
| hasUnderlyingCompanyPrimaryBusiness | development of antibody-based therapies ⓘ |
| hasUnderlyingCompanyRAndDFocus |
genetics-based drug discovery
ⓘ
monoclonal antibodies ⓘ |
| hasUnderlyingCompanyResearchCollaboration | Regeneron Genetics Center NERFINISHED ⓘ |
| hasUnderlyingCompanyStateOfIncorporation | New York NERFINISHED ⓘ |
| hasUnderlyingCompanyStockCategory | large-cap biotechnology stock ⓘ |
| hasUnderlyingCompanyTechnologyPlatform | VelocImmune antibody technology NERFINISHED ⓘ |
| hasUnderlyingCompanyTherapeuticArea |
cardiovascular diseases
ⓘ
immunology ⓘ oncology ⓘ ophthalmology ⓘ |
| hasUnderlyingCompanyTicker | REGN NERFINISHED ⓘ |
| hasUnderlyingCompanyType | public company ⓘ |
| hasUnderlyingCompanyWebsite | https://www.regeneron.com ⓘ |
| isComponentOfIndex |
NASDAQ Biotechnology Index (NBI)
NERFINISHED
ⓘ
S&P 500 Index NERFINISHED ⓘ |
| listedOn | NASDAQ ⓘ |
| regulatoryJurisdiction | U.S. Securities and Exchange Commission NERFINISHED ⓘ |
| represents | Regeneron Pharmaceuticals, Inc. NERFINISHED ⓘ |
| securityType | common stock ⓘ |
| tradedAs | REGN NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.